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Abstract: Regular red cell transfusion therapy ameliorates disease-related morbidity and can be 
lifesaving in patients with various hematological disorders. Transfusion therapy, however, causes 
progressive iron loading, which, if untreated, results in endocrinopathies, cardiac arrhythmias 
and congestive heart failure, hepatic fibrosis, and premature death. Iron chelation therapy is used 
to prevent iron loading, remove excess accumulated iron, detoxify iron, and reverse some 
of the iron-related complications. Three chelators have undergone extensive testing to date: 
deferoxamine, deferasirox, and deferiprone (although the latter drug is not currently licensed 
for use in North America where it is available only through compassionate use programs and 
research protocols). These chelators differ in their modes of administration, pharmacokinetics, 
efficacy with regard to organ-specific iron removal, and adverse-effect profiles. These differential 
properties influence acceptability, tolerability and adherence to therapy, and, ultimately, the 
effectiveness of treatment. Chelation therapy, therefore, must be individualized, taking into 
account patient preferences, toxicities, ongoing transfusional iron intake, and the degree of 
cardiac and hepatic iron loading.
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Iron overload
Transfusional iron overload
Regular red cell transfusions are used in the management of numerous hematological 
disorders including beta-thalassemia major; sickle cell disease; other hemolytic anemias, 
such as pyruvate kinase deficiency; bone marrow failure syndromes; and myelodysplastic 
syndromes. Each milliliter of packed red blood cells contains 1.1 mg of iron. Because 
humans lack physiological mechanisms to excrete excess iron, chronic red cell trans-
fusion therapy will lead to progressive iron accumulation in the absence of chelation 
therapy. A typical regular transfusion regimen leads to an average iron accumulation 
of approximately 0.3–0.5 mg/kg/day,1,2 although there is considerable interpatient 
variability in iron loading. In one study of 541 patients with beta thalassemia, 61% 
had transfusional iron intakes in the range 0.3–0.5 mg/kg/day, while 19% and 20% 
had average iron intakes below and above this range, respectively.1 Chelation therapy is 
necessary to remove this iron accumulation to prevent or treat its associated toxicity.
Nontransfusional iron overload
Iron overload also can result from hereditary causes that lead to increased intestinal 
absorption of dietary iron. Dysregulation of hepcidin, a small peptide produced mainly Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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in the liver that inhibits iron absorption, now appears to be 
central in many of the hereditary forms of hemochromatosis. 
The most common form of hereditary hemochromatosis is 
caused by mutations in the HFE gene, which prevent the 
appropriate upregulation of hepcidin expression in response 
to increased iron levels.3 Homozygosity for the cysteine to 
tyrosine substitution (C282Y) in the human hemochromatosis 
(HFE) protein is associated with the development of iron 
overload typically in the fifth to sixth decades of life, although 
clinical penetrance is variable.4 The standard treatment for 
hereditary hemochromatosis is phlebotomy to reduce iron 
stores, although iron chelation therapy may be used in patients 
who are unable to tolerate the procedure.5
Gastrointestinal iron absorption also is greatly increased 
in patients with ineffective erythropoiesis such as thalassemia 
intermedia and in some red cell enzyme deficiencies, 
  particularly pyruvate kinase deficiency. The pathophysiology 
may be related to elevated levels of GDF15, a bone marrow–
derived factor that suppresses hepcidin expression.6,7 The 
resulting increased absorption of dietary iron can cause iron 
overload, which may be further exacerbated by periodic 
transfusions. Serial phlebotomy is impractical for many 
patients with congenital anemias because of the level of 
anemia, and chelation therapy is effective in reducing iron 
burden in these patients.8–11
The remainder of this review focuses on the management 
of transfusional iron overload including monitoring and 
treatment with chelation. The majority of data regarding 
chelation therapy has been derived from the thalassemia 
population and is the focus of this review; important 
differences relevant to other transfused populations are 
highlighted where possible.
Toxicity related to iron overload
Free iron is toxic to cells; normally, in the body iron is tightly 
complexed with proteins, protecting the cells from free iron. 
The main storage complex of iron is ferritin, which is found 
principally in the liver, reticuloendothelial cells, and red 
cell precursors; small amounts of ferritin are also found in 
the blood, allowing for easy measurement. In plasma, iron 
is bound to transferrin, which transports iron to the cells. 
In iron overload states, high levels of iron exceed the iron-
carrying capacity of transferrin within the plasma, leading 
to the formation of nontransferrin-bound iron forms.12 These 
nontransferrin-bound iron forms can be taken up into cells, 
including liver, heart, and endocrine cells, where the iron 
can participate in the generation of free radicals through 
Fenton’s reaction:
Fe2+ + H2O2 → Fe3+ + OH- + HO•
These free radicals cause lipid peroxidation and organelle 
damage leading to organ toxicity. The organs most susceptible 
to iron-related injury include the heart, liver, and endocrine 
organs. Cardiac toxicity includes congestive heart failure and 
arrhythmias and is the leading cause of death related to iron 
overload in patients with thalassemia major.13 Excess iron 
deposition in the liver leads to inflammation, fibrosis, and 
cirrhosis,14 which may be further exacerbated by concomitant 
viral hepatitis, alcohol use, and other hepatotoxins. Iron 
is also toxic to the endocrine organs, leading to growth 
failure, delayed puberty,15 hypogonadotropic hypogonadism, 
diabetes mellitus, osteopenia, hypothyroidism, and 
hypoparathyroidism.16 Endocrinopathies are a significant 
cause of morbidity in chronically transfused patients: 
among 342 North American patients with transfusion-
dependent thalassemia, 38% had at least one endocrinopathy, 
most commonly hypogonadism, and the prevalence of 
endocrine abnormalities increased with age.16 Similarly, in 
a French cohort of 215 chronically transfused patients with 
thalassemia, 47.8% had hypogonadism, 6% diabetes, and 
9.9% hypothyroidism.17
Monitoring iron burden
Multiple methods of assessing the degree of iron overload 
exist, and each method has benefits and limitations. In clinical 
practice, combinations of the different techniques and serial 
measurements are utilized to assess iron burden and to adjust 
chelation therapy. Tables 1 and 2 provide a summary of the 
clinical implications of various iron measurements.
Serum ferritin level can be measured frequently via 
blood testing and is particularly useful to monitor trends in 
iron burden over time. The ferritin level correlates with total 
body iron burden in chronically transfused patients, although 
this correlation is not precise.18 Furthermore, changes in the 
serum ferritin level in response to chelation have been shown 
to parallel changes in liver iron concentration measured by 
both liver biopsy and noninvasive means.19,20 The ferritin 
level also has prognostic significance: sustained levels of over 
2500 mg/mL are associated with an increased risk of cardiac 
toxicity and death in patients with thalassemia.21,22
Unfortunately, a variety of disease states, including infec-
tion, inflammation, and ascorbate deficiency, can either raise 
or lower serum ferritin levels. This limitation of ferritin in 
predicting iron stores is particularly relevant for patients with 
sickle cell disease. For example, great variability in the rate of 
rise of serum ferritin level was evidenced among 50 children 
with sickle cell disease receiving similar transfusion programs Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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for primary stroke prevention.23 Despite this   limitation, the 
serum ferritin level still may be useful in sickle cell disease: 
very high ferritin levels above 3000 ng/mL generally predict a 
liver iron concentration of 10 mg/g dry weight (dw) or higher, 
while ferritin levels below 1500 ng/mL usually correlate with 
a liver iron concentration below 10 mg/g dw.24 Serum ferritin 
level also underestimates liver iron concentration in patients 
with thalassemia intermedia and nontransfusion-associated 
iron overload.25
Given that the liver is the major target organ for iron 
accumulation following multiple transfusions, the liver iron 
concentration is a good indicator of total iron burden.26 In 
untransfused individuals, the normal liver iron concentration 
ranges from 0.17 to 1.8 mg Fe/g dw. Traditionally, chelation 
therapy has been dosed to maintain slightly higher liver 
iron concentrations of 3 to ,7 mg Fe/g dw of liver, a 
level of hepatic iron burden that is seen in asymptomatic 
heterozygotes for hereditary hemochromatosis.27 More 
aggressive chelation regimens have been advocated recently, 
with a goal to achieve and maintain “normal” body iron 
stores,28 although the risk of toxicity with “overchelation” 
must be considered. Liver iron concentration also has 
prognostic significance in patients with thalassemia. Levels 
in excess of 15 mg Fe/g dw of liver are associated with 
an increased risk of cardiac complications and death,21,22 
although the inverse is not always true: high levels of cardiac 
iron and iron-related cardiac disease can be seen despite low 
liver iron concentrations, due to differential rates of iron 
loading and unloading in these organs.29,30
Various methods are available to estimate liver iron 
  concentration. Liver biopsy is generally considered to be 
the gold standard for accurate iron measurement and allows 
for direct assessment of liver inflammation and fibrosis. 
However, a number of limitations to liver biopsy exist: it is 
an invasive procedure, with risks including bleeding, bile 
leak, and pain; liver fibrosis and cirrhosis cause an uneven 
distribution of iron, which may lead to an underestimation 
of liver iron in patients with advanced liver disease;31 and 
sample size also affects the accuracy of iron measurement – 
samples that are at least 1 mg dw correlate better with iron 
burden than do smaller samples.26
The superconducting quantum interference device 
(SQUID) technique uses magnetometers to measure very 
small magnetic fields and can be used as a noninvasive 
technique to measure ferritin and hemosiderin in the liver.32 
Estimation of liver iron concentration by SQUID correlates 
linearly with concentrations measured by liver biopsy.32 Since 
this is a noninvasive technique, repetitive iron concentration 
measurements by SQUID have been utilized to monitor the 
efficacy of chelation in a number of studies.20,33–35 The biggest 
limitation to using SQUID is that it is a highly specialized and 
expensive approach and few sites worldwide offer the tech-
nology, limiting its accessibility to patients. In recent clinical 
trials, SQUID measurements also underestimated liver iron 
concentrations obtained by biopsy by approximately 50%,19 
though the correlation is good when accurate conversion 
factors from wet to dry weight of liver are utilized.36
Magnetic resonance imaging (MRI) is increasingly 
being used to monitor iron overload. This technique takes 
advantage of local inhomogeneities of the magnetic field 
caused by iron deposition in tissues.37 Magnetic resonance 
Table 2 Clinical implications of cardiac iron assessment by T2* 
magnetic resonance imaging
Cardiac T2* (ms) Clinical implication
20 No significant cardiac iron loading; continue 
current chelation
10 to ,20 Mild to moderate cardiac iron loading with 
increased risk of cardiac complications; 
consider intensification of chelation such as 
increased dosea and/or continuous infusion 
(for deferoxamine); combination therapy with 
deferiprone and deferoxamine if available
,10 Severe cardiac iron loading with high risk of 
cardiac complications; intensify chelation such 
as increased dosea and/or continuous infusion 
(for deferoxamine); combination therapy with 
deferiprone and deferoxamine if available
Note: aChelator dose should not exceed approved range (see Table 3).
Table  1  Clinical  implication  of  ferritin  levels  and  liver  iron 
concentration
Liver iron 
concentration 
(mg/g dw)
Ferritin levela  
(ng/mL)
Clinical implications
,2 ,500 Low iron stores; consider 
decreasing or holding 
chelation temporarilyb
2–7 500–1499 Ideal range; continue current 
chelation
.7–15 1500–2500 Increased iron stores; increase 
chelator dosec and/or change 
chelator if ferritin and/or liver 
iron trend is not improving
.15 .2500 elevated iron stores 
associated with increased risk 
of complications and death; 
increase chelator dosec and/
or change chelator; consider 
combination chelation therapy
Notes: aFerritin should be obtained when patient is clinically well and vitamin C 
replete;  bchelation should not be held if cardiac iron loading is present (cardiac 
T2* ,20 ms) ; cchelator dose should not exceed approved range (see Table 3).Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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images darken at a rate proportional to the iron concentration. 
T2 and T2* refer to the half-life of darkening and these 
values are inversely proportional to the amount of iron 
accumulation in the organ. The reciprocals of T2 and T2*, 
known as R2 and R2*, respectively, refer to rates of signal 
decay and are directly proportional to iron concentration.38 
While MRI has been used to estimate iron levels in a 
  variety of organs including the pituitary, pancreas, and bone 
  marrow, it is most commonly used to measure hepatic39 and 
cardiac iron.29,40 Studies using R2 to estimate liver iron have 
shown good   correlation with iron levels determined by liver 
biopsy, as well as reproducibility across different scanners.39 
Other approaches using T2* or R2* are also promising for 
determining liver iron content.29,41
Most important, cardiac iron levels also can be   estimated 
using MRI, most commonly with T2* measurements. 
Determination of cardiac iron is particularly helpful because 
cardiac disease is the leading cause of death in patients with 
thalassemia and transfusional iron overload.13 Cardiac T2* 
values below 20 ms indicate mild to moderate cardiac iron 
overload, while levels below 10 ms are associated with 
an increased risk of cardiac disease including ventricular 
  dysfunction and arrhythmias (Table 2).29,40 Patients with 
T2* values below 6 ms have a 47% chance of developing 
congestive heart failure within the next year.42 Thus, patients 
with low cardiac T2* values require intensification of 
chelation therapy.
Magnetic resonance scanners are more widely available 
than SQUID, and this technique is now available in many 
sites throughout the world. Limitations include the need 
for specialized programming and expertise in these MRI 
techniques. In addition, MRI is costly, making frequent 
monitoring prohibitive.
Most knowledge of the complications of iron overload 
comes from patients with thalassemia who require lifelong 
red blood cell transfusions, which are usually initiated within 
the first few years of life. Patients with different diseases 
requiring chronic transfusions, particularly sickle cell disease 
and Diamond–Blackfan anemia, appear to differ somewhat 
with respect to organ-specific transfusional iron loading.43–45 
For example, iron-related cardiomyopathy and diabetes 
are less common in sickle cell disease than thalassemia 
despite comparable transfusion burdens,43,46 a finding that is 
paralleled by reduced iron loading in the heart and pancreas 
in sickle cell patients.44,47 In contrast, it was observed that 
liver iron concentration was higher in transfusion-dependent 
Diamond–Blackfan anemia patients than in thalassemia 
patients matched for age and iron intake.45 Variability in 
the duration of iron exposure, treatment with chelation, or 
processing of iron among underlying disease states may all 
contribute to the differences in organ-specific iron loading. 
Nonetheless, given the lack of substantial information about 
disease-specific responses to iron overload, data from the 
thalassemia population continue to guide monitoring and 
treatment for other transfused patient populations, although 
ongoing research studies may provide future insight into 
better disease-specific approaches.
Overview of chelation
The goal of chelation therapy is to maintain “safe” body iron 
levels to prevent the development of organ toxicities. Ideally, 
for patients who are regularly transfused, chelation should be 
administered in a manner to prevent excess iron accumulation 
by matching the ongoing transfusional iron intake. Chelators 
also bind nontransferrin-bound iron forms, protecting vul-
nerable organs such as the heart from damage by these toxic 
iron forms, and continuous chelator exposure is optimal in 
this regard. In practice, however, chelation therapy is often 
utilized to remove excess stored iron. Once iron-related organ 
toxicity has developed, chelation therapy can reverse some, 
but not all, of the complications.28,48
Differential properties of chelators
A variety of factors differentiate the currently available iron 
chelators. First, pharmacological properties, including the 
stoichiometry of iron chelation, mode of administration, 
dosing schedule, plasma half-life, and route of excretion, vary 
among chelators. Second, drug efficacy is variable, particularly 
with regard to organ-specific (hepatic, cardiac) iron removal. 
Third, adverse-effect profiles differ among chelators. 
These various drug properties ultimately contribute to 
patient adherence, overall control of iron burden, and the 
complication profile. Differential properties of the iron 
chelators are summarized in Table 3 and the following 
sections provide detailed information for each of the 
currently available iron chelators. Chelation therapy needs 
to be individualized; the choice of chelator(s) and dosing 
should be made based on: drug availability and tolerability 
(including adverse effects), patient preference and ability 
to adhere to the regimen, ongoing transfusion burden, and 
trends in organ-specific iron loading.
Deferoxamine
Pharmacology
Deferoxamine, a naturally occurring iron chelator produced 
by Streptomyces pilosus, was the first approved iron chelator Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
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and has been used in routine clinical practice for more 
than 40 years.49 It is a hexadentate iron chelator that binds 
iron stably in a 1:1 ratio (Table 3). Deferoxamine is not 
well absorbed from the gastrointestinal tract so it must be 
administered parenterally.50 Furthermore, the drug’s plasma 
half-life is very short at approximately 20 minutes.50 Thus, 
deferoxamine is usually administered as a continuous 
infusion of 25 to 50 mg/kg given over 8 to 12 hours, 5 to 
7 days per week either subcutaneously or intravenously. 
Because the drug’s half-life is short, the chelator is rapidly 
cleared after the infusion is completed and the drug is no 
longer available to bind and detoxify iron. Thus, intravenous 
administration of longer durations of up to 24 hours daily 
is often employed for patients with high iron burden and/
or evidence of cardiac iron loading or iron-related cardiac 
toxicity. Very high dosing of deferoxamine (such as 
10 mg/kg/hour) has been utilized in the past.51 However, 
acute pulmonary and neurotoxicity may develop with higher 
doses,52,53 so, in general, doses .60 mg/kg/day should be 
avoided. Excretion of iron bound to deferoxamine occurs 
through both the urine and feces.
The parenteral mode of administration is painful and time 
consuming, which can adversely affect treatment adherence. To 
overcome this limitation, alternative modes of administration 
have been investigated. Twice-daily bolus injections of 1000 mg 
of deferoxamine diluted in 10 mL of distilled water have been 
administered. Iron excretion with bolus injection was similar to 
that seen with subcutaneous infusion.54   Unfortunately, painful 
swelling that lasted for several hours following injection led 
many patients to discontinue this treatment55 and, thus, this 
mode of administration is infrequently utilized.
Efficacy
The efficacy of deferoxamine is well established. The drug 
induces substantial iron excretion and can induce a net 
negative iron balance56 in chronically transfused patients. Iron 
excretion is hindered in the presence of vitamin C deficiency, a 
common consequence of iron overload. Oral supplementation 
with vitamin C increases urinary iron excretion with 
deferoxamine, but excessive vitamin C can also increase the 
toxicity of iron.57 Thus, patients with documented vitamin C 
deficiency are usually treated with 100 mg of vitamin C 
orally, given only at the time of deferoxamine infusion. 
Multiple studies dating back over three decades have shown 
that regular administration of deferoxamine effectively 
lowers serum ferritin levels.19,58,59 Chelation therapy with 
deferoxamine can also prevent other organ toxicities such as 
diabetes and other endocrinopathies.49,60
Hepatic iron removal
In the 1970s, regular intramuscular administration of 
deferoxamine therapy was shown to reduce hepatic iron 
Table 3 Properties of iron chelators
Property Deferoxamine Deferasirox Deferiprone
Stoichiometry 
(chelator: iron)
Hexadentate (1:1) Tridentate (2:1) Bidentate (3:1)
Usual dose 25–60 mg/kg/day 
over 8–24 hours
20–40 mg/kg/day 
once daily
75–100 mg/kg/day 
in three divided doses
Route of administration Subcutaneous, intravenous Orally dispersible tablet Oral tablet or suspension
Half-life 20–30 minutes 7–16 hours 1.5–2.5 hours
excretion Urinary, fecal Fecal Urinary
Ability to remove liver iron +++ +++ ++*
Ability to remove cardiac iron ++# ++** +++
Typical adverse events Local reactions 
Sensorineural hearing loss 
Ophthalmic changes 
Allergic reactions 
Bone abnormalities 
increased risk of Yersinia  
and Klebsiella infections 
Pulmonary at high doses 
Neurological at high doses
Gastrointestinal 
Rash 
Rise in creatinine 
Proteinuria 
elevated hepatic enzymes 
Gastrointestinal bleeding (rare) 
Fulminant hepatic failure (rare) 
Renal insufficiency (rare)
Gastrointestinal 
Neutropenia/Agranulocytosis 
Arthralgia 
elevated hepatic enzymes
Availability Licensed Licensed Licensed in europe and Asia as  
second-line agent; not licensed in North America
Notes: *Reports of insufficient liver iron removal in some patients at doses of 75 mg/kg/day, but higher dosing, especially for subjects with high transfusional iron burden 
may be more effective; #with continuous infusion; **data are limited regarding efficacy with very low cardiac T2* and in heart failure; cardiac iron removal also may be less 
effective in patients with high liver iron concentration.Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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accumulation and slow the progression of hepatic fibrosis.61 
Subsequently, in the early 1980s, daily subcutaneous continu-
ous infusion of deferoxamine was shown to reduce hepatic 
iron content to normal or near-normal levels in chronically 
transfused patients with thalassemia.62 Recent clinical trials 
have continued to show the efficacy of deferoxamine in 
hepatic iron removal in patients with transfusion-dependent 
anemias.19,20 Nonetheless, the improvement in liver iron 
concentration correlates with the rate of transfusional iron 
intake.1 Patients with higher transfusional iron intake gener-
ally require more chelator, which may be achieved by admin-
istering deferoxamine for a greater number of days per week 
and/or at the higher end of the therapeutic dose range.
Cardiac iron removal
Most important, the regular use of deferoxamine is associated 
with a reduced incidence of cardiac complications and 
death.21,49,59 In addition, deferoxamine, usually given in 
higher doses up to 60 mg/kg/day as a continuous intravenous 
infusion, can reverse cardiac complications.63 Cardiac 
iron burden as measured by T2* MRI also improves with 
continuous infusion of deferoxamine.48
Adverse effects
Local infusion site reactions, including induration and 
erythema, are commonly seen with administration of 
deferoxamine. Allergic reactions can also develop. Other 
adverse effects – including high-frequency hearing loss; 
ophthalmologic toxicity;64 growth retardation; and skeletal 
changes, including rickets-like lesions and genu valgum in 
growing children65 – are more common when patients receive 
high doses of deferoxamine relative to their total body iron 
burden. Ocular and audiological toxicity can be minimized 
by maintaining a ratio of deferoxamine dose (mg per kg 
of body weight) to the serum ferritin level below 0.025.66 
Increased risk of infection with Yersinia and Klebsiella 
species in patients with iron overload may be exacerbated 
by use of this chelator.67,68 Low zinc levels can also develop 
with deferoxamine use, and levels of this trace element 
should be measured periodically. Acute pulmonary toxicity 
with respiratory distress, hypoxemia, and a diffuse interstitial 
pattern on chest roentgenogram, and acute neurotoxicity have 
both been reported with the administration of very high doses 
of deferoxamine (10–20 mg/kg/hr).52,53
Adherence
The greatest challenge with deferoxamine is patient 
adherence, because the need for parenteral administration 
is cumbersome, uncomfortable, inconvenient, and time 
consuming. A recent review of published studies showed 
compliance rates with deferoxamine to range from 59% to 
78%.69 Older age70 and concomitant psychiatric disorders71 
have been found to predict poor adherence. Patient-reported 
reasons for missing deferoxamine doses included patients’ 
feelings and beliefs, adverse effects, and lack of support from 
others.70 Considerable morbidity and preventable, premature 
iron-related deaths continue to occur in patients treated with 
deferoxamine, which are probably related to difficulties with 
adherence.72,73
Deferiprone
Pharmacology
Deferiprone  (1,2-dimethyl-3-hydroxypyrid-4-one), 
introduced into clinical trials in the 1980s, was the first 
oral chelator to undergo extensive testing. This chelator 
was designed by modifying siderophore chemistry.74 Most 
studies of the drug have involved open-label, noncomparative 
studies, often including patients with a history of inadequate 
iron chelation, but a few randomized trials comparing 
deferiprone with deferoxamine have been reported. 
A substantial amount of data on the safety and efficacy of 
the drug has been acquired but considerable controversy 
surrounds the drug. Deferiprone is approved for use in the 
European Union and other countries for patients in whom 
deferoxamine therapy is inadequate or not tolerated, but the 
drug has not been approved for use in North America and 
is currently only available to a limited number of patients 
through compassionate use programs or research trials.
Deferiprone is a bidentate chelator, meaning that three 
molecules of the drug are required to bind iron fully. Given 
its relatively short plasma half-life of 1.5 to 2.5 hours,75,76 
the drug usually is dosed three times daily. The typical 
daily dose is 75 mg/kg, but doses of up to 100 mg/kg/day 
are approved in Europe. The drug is available as 500 mg 
tablets or as an oral solution (100 mg/mL), which has been 
shown to have a similar safety and efficacy profile to the 
tablet form.77 Deferiprone induces iron excretion almost 
exclusively in the urine, with minimal contribution from 
fecal elimination.78,79
Efficacy
Urinary iron excretion with deferiprone at doses of 
75 mg/kg is comparable to that induced by deferoxamine 
at a dose of 50 mg/kg.78,79 The mean urinary iron excre-
tion with deferiprone at 75 mg/kg was 0.48 mg/kg/day in 
one study,78 a level that would be predicted to maintain or Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
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decrease iron stores in most patients; however, significant 
interpatient variability exists. Higher doses of deferiprone, 
90–119 mg/kg, induced greater urinary iron excretion and 
may be beneficial for patients with inadequate responses 
at lower doses.80–82 Current European product labeling, 
however, cautions against using doses above 100 mg/kg/day 
due to the potential for increased toxicity.
Short- and long-term studies of treatment with deferiprone 
for transfusional iron overload have generally shown a 
reduction35,80,83–86 or stabilization87–89 in mean serum ferritin 
levels. Similar responses have been shown across different 
disease states including sickle cell disease and thalassemia. 
However, a small proportion of patients demonstrated a 
significant increase in serum ferritin levels while receiving 
long-term deferiprone.35,86,88,89 In a group of 151 Italian 
patients who received deferiprone for 3 years or more, 20% 
had clinically significant rises in ferritin levels.86
Hepatic iron removal
Studies on the effect of chelation with deferiprone on liver 
iron concentration have also shown mixed results.35,84,88,90,91 
In a report of 21 patients who received deferiprone at 
75 mg/kg/day, mean liver iron concentration assessed by 
biopsy or SQUID, decreased from 15 to 8.7 mg/g dw liver, 
after a mean treatment duration of 3.1 years.35 With longer 
follow-up of a mean of 4.6 years in 18 patients, there was an 
overall reduction in liver iron concentration from baseline 
(16.5–12.1 mg/g dw, P = 0.07), but the liver iron concentra-
tion still remained at a concerning level above 15 mg/g dw in 
seven patients.91 In another report of 20 patients who received 
deferiprone (70 mg/kg/day) for 1 year or more, the mean liver 
iron concentration increased from 16 to 21 mg/g dw, although 
this change did not reach statistical significance.90 Liver 
iron content decreased in seven patients, rose in 12 patients, 
and remained the same in one patient. Thus, chelation with 
deferiprone at a dose of 70–75 mg/kg/day may not reduce 
liver iron concentration effectively in some patients.
Although there are few randomized trials comparing 
deferiprone with deferoxamine, these studies have generally 
shown the two drugs have comparable efficacy with regard 
to hepatic iron removal. In one study of 144 subjects, the 
reduction in serum ferritin levels was similar between 
treatment groups (deferiprone 75 mg/kg/day compared with 
deferoxamine 50 mg/kg/day) and mean reduction in liver iron 
concentration was also similar among a subset of 36 subjects 
who underwent liver biopsy.84 Similarly, in a more recent 
study of 61 patients randomized to receive either deferox-
amine at 50 mg/kg/day for 5 days per week or deferiprone 
(75 mg/kg/day initially, then increasing to 100 mg/kg/day) 
changes in liver iron concentration over the 1-year period did 
not significantly differ between the two groups.92
The lack of reduction in serum ferritin levels or liver iron 
concentration in some patients receiving deferiprone may 
be explained by a variety of reasons including individual 
differences in pharmacokinetics, inadequate adherence 
with therapy, or higher transfusional iron intake. Increasing 
the dosage of deferiprone might help overcome some of 
these issues. In one study, increasing the daily dose of 
deferiprone from 75 mg/kg to 83–100 mg/kg resulted in a 
reduction in serum ferritin level in nine patients who had 
received inadequate chelation at the lower dose.82 Similarly, 
in a study of twelve transfused thalassemia patients, the 
mean serum ferritin level significantly improved from 
3901 ng/mL to 2205 ng/mL after 2 years of treatment with 
deferiprone at 100 mg/kg/day and no increased toxicity 
was observed.93
Cardiac iron removal
Deferiprone is a small molecule that is lipophilic, enabling 
entry into myocytes, and this chelator appears to be 
particularly efficacious in cardiac iron removal. Retrospective 
studies have demonstrated reduced cardiac morbidity 
and mortality94,95 and lower myocardial iron deposition96 
among patients treated with deferiprone compared with 
deferoxamine. Furthermore, in a randomized controlled 
trial of 61 beta-thalassemia patients with moderate cardiac 
siderosis (T2* 8 to ,20 ms) and normal cardiac function, 
a significantly greater improvement in cardiac T2* and 
left ventricular function was seen with treatment with 
deferiprone compared with deferoxamine.92 In a large clinical 
observational study, treatment with deferiprone resulted in 
improvement in cardiac T2* among patients with all degrees 
of cardiac iron loading (including severe iron loading with 
T2* ,8 ms) and treatment with deferiprone resulted in 
a significantly greater overall reduction in cardiac iron 
compared with deferasirox.97
Adverse effects
The most serious adverse event associated with deferiprone 
is agranulocytosis. In a multicenter study of 187 patients with 
thalassemia major treated with deferiprone in which weekly 
blood counts were monitored, the incidence of agranulocytosis 
(absolute neutrophil count ,500 × 109/L) was 0.6 per 100 
patient-years and the incidence of milder neutropenia   (absolute 
neutrophil count 500 to 1500 × 109/L) was 2.8 per 100 patient-
years.87 In the largest study reported to date, similar rates of Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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0.2 per 100 patient-years for agranulocytosis and 2.1 per 
100 for neutropenia were reported.86 Neutropenia is usually 
reversible with discontinuation of the drug but often recurs 
with reinstitution of therapy.86,98 In clinical practice, weekly 
blood counts are recommended, which can be inconvenient 
for patients, to monitor for this side effect. Treatment with 
deferiprone may not be appropriate for patients with under-
lying bone-marrow failure syndromes, such as Diamond–
Blackfan anemia or myelodysplastic syndromes, who may 
be more likely to develop agranulocytosis or neutropenia.99,100 
Similarly, caution should be exercised when using this drug 
in combination with hydroxyurea, interferon, or other drugs 
that can cause neutropenia.
Gastrointestinal symptoms including nausea, vomiting, 
diarrhea, and abdominal pain are common side effects 
reported with deferiprone, occurring in 33% of subjects in one 
large study.89 These symptoms usually improve after the first 
few weeks of treatment and rarely require discontinuation 
of therapy.86,87 Arthropathy with pain and/or swelling of the 
knees and other large joints is another common complication, 
and can occur early or late in treatment.85,86,89 In a large 
study of 532 patients, the prevalence of this complication 
was only 4%,86 but other studies have reported higher rates 
of up to 38.5%.80 The arthropathy is usually reversible with 
discontinuation of the drug.80,87 Low plasma zinc levels have 
also developed in a minority of patients receiving deferiprone, 
thus periodic monitoring of zinc levels is warranted.80,87
Elevations in serum alanine aminotransferase (ALT) can 
occur with drug administration but are often transient and 
resolve even with continued drug administration at the same 
or reduced dose.85,86 Patients with hepatitis C infection86,87 or 
higher hepatic iron concentrations86 may be more likely to 
develop ALT elevations. Concerns have been raised about 
the possible progression of hepatic fibrosis with deferiprone 
therapy.91 In a retrospective study, progression of hepatic 
fibrosis was seen among five of 14 patients after a mean 
duration of 2.3 years of treatment with deferiprone; four of 
the subjects with progression of fibrosis also had concomitant 
hepatitis C infection.91 In contrast, no fibrosis was seen in 
12 subjects treated with deferoxamine, five of whom were 
hepatitis C seropositive.91 The contribution of deferiprone 
to the development of fibrosis in these patients is difficult to 
decipher given that the majority of subjects who developed 
fibrosis had concomitant hepatitis C infection, which can 
cause hepatic fibrosis itself. Furthermore, the effect of 
deferiprone on hepatic fibrosis has not been confirmed 
in follow-up studies.101,102 In the largest study to date, no 
significant progression of  fibrosis was observed in 56 patients 
(11 seropositive for hepatitis C) with liver biopsy specimens 
obtained before and after treatment with deferiprone at a 
mean interval of 3.1 years.102
Adherence
In a review of studies assessing adherence with treatment with 
deferiprone, overall compliance ranged from 79% to 96%.69 
In these studies, adherence was monitored by pill counts, 
patient report, physician assessment, and/or medication 
event monitoring system. Similarly, comparative studies of 
adherence with deferoxamine versus deferiprone suggest 
overall better compliance with the oral chelator.69
Deferasirox
Pharmacology
Deferasirox is the first oral iron chelator approved for use 
in the USA, and it has also been approved in a number of 
other countries (Table 3). Deferasirox, a triazole compound, 
was designed using computer-aided molecular modeling.103 
Deferasirox binds iron in a 2:1 ratio (tridentate chelator). 
The drug has a high specificity for iron, with minimal 
binding to copper and zinc. Deferasirox is supplied as 
orally dispersible tablets that are dissolved in water or 
juice and should be administered on an empty stomach 
at least 1/2 hour before a meal.104 Deferasirox is rapidly 
absorbed, achieving peak plasma levels within 1–3 hours 
after administration. Its half-life ranges from 7 to 16 hours,34 
and is longer with higher doses,103 supporting a once-daily 
dosing regimen. The deferasirox-iron complex is excreted 
almost exclusively in the feces, with minimal urinary 
excretion.103 Mean iron excretion was 0.3 mg/kg/day with 
a deferasirox dose of 20 mg/kg and rose to 0.5 mg/kg/day 
with a 40 mg/kg dose.105
Efficacy
Hepatic iron and ferritin levels
Deferasirox in doses of 20–30 mg/kg/day was shown 
to have similar efficacy to deferoxamine with regard to 
reduction in liver iron concentration and serum ferritin 
levels in a randomized trial of 586 patients with thalas-
semia major.19 In that trial, four different dose levels of 
deferasirox were tested (5, 10, 20, and 30 mg/kg), with 
initial dosing determined according to baseline liver iron 
concentration (lower doses for lower liver iron concentra-
tions). A similar dosing algorithm was utilized for defer-
oxamine in that study, but subjects were allowed to remain 
on their prestudy deferoxamine dose, which resulted in 
proportionately higher deferoxamine than deferasirox Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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doses in the lowest two liver iron concentration groups. 
The primary objective of noninferiority of deferasirox to 
deferoxamine across all treatment groups was not attained, 
which was probably related to this relative underdosing 
of deferasirox in the lowest two dose groups. However, 
noninferiority of deferasirox was demonstrated at the 20 
and 30 mg/kg dose groups. The average reduction in liver 
iron concentration over the 1-year treatment period with 
deferasirox at 20 or 30 mg/kg was 5.3 ± 8.0 mg/g dw, 
compared with a reduction of 4.3 ± 5.8 mg/g dw with 
deferoxamine, P = 0.367.19 Trends in serum ferritin levels 
over the course of the study paralleled the changes in liver 
iron concentration.
Phase II studies in patients with other transfusion-
dependent anemias have demonstrated similar results. In 
a multicenter study, 195 patients with sickle cell disease 
were randomized to receive deferasirox (10–30 mg/kg/day) 
or deferoxamine (20 to 50 mg/kg, 5 days per week) with 
dosing based on the pretreatment liver iron content.20 A mean 
reduction in liver iron concentration of 3 mg/g dw, was seen 
after 1 year of treatment with deferasirox, comparable to 
the decrease in liver iron concentration seen with defer-
oxamine (2.8 mg/g dw). Similarly, an overall significant 
reduction in liver iron concentration was seen in a Phase II 
study of 184 patients with myelodysplasia, thalassemia, 
Diamond–Blackfan anemia, and other rare transfusion-
dependent anemias, in patients who received deferasirox at 
20–30 mg/kg for a period of 1 year.2
Subsequent analyses have shown that the response 
to deferasirox is dependent on ongoing tranfusional 
requirements. For most patients with transfusional iron 
intake averaging ,0.3 mg/kg/day, a dose of 20 mg/kg of 
deferasirox was effective in reducing liver iron concentration, 
while in over 50% of patients with the highest iron intake 
of .0.5 mg/kg/day, the dose of 20 mg/kg/day did not reduce 
liver iron concentration effectively.1 In addition to ongoing 
transfusional iron intake, individual variability in drug 
pharmacokinetics may impact response to deferasirox.106 
Both of these factors might be addressed by using higher 
doses of the drug. A subanalysis of 264 subjects treated with 
deferasirox at doses .30 mg/kg/day for a median duration of 
36 months demonstrated a reduction in serum ferritin levels 
without increased toxicity.107 Currently, doses of deferasirox 
of up to 40 mg/kg/day are approved for use. Dosing of 
deferasirox should be guided by the goal of maintenance 
or reduction of body iron stores, ongoing transfusional 
requirements, and trends in ferritin and liver iron content 
during treatment.
Cardiac iron removal
Early clinical data suggest that deferasirox is able to remove 
cardiac iron. In a prospective study of 114 patients with 
thalassemia and evidence of cardiac iron loading (cardiac 
T2* values of 5 to ,20 ms) but normal left ventricular 
function, cardiac T2* significantly improved from a mean of 
11.2 to 12.9 ms after 12 months of treatment with deferasirox 
at a mean dose of 32.6 mg/kg/day.108 A further improvement 
in cardiac T2* to 14.8 ms was seen with an additional 
year of treatment at a mean dose of 36.1 mg/kg/day.109 
A concomitant significant reduction in serum ferritin 
levels and liver iron concentration was demonstrated. 
Interestingly, there was no significant improvement in left 
ventricular ejection fraction (LVEF) over the 2 years of study, 
although the ejection fraction was normal at baseline.109 
Nonetheless, significant improvement in LVEF has been 
demonstrated with deferiprone in a group of patients with a 
similar degree of cardiac iron loading and normal baseline 
LVEF,92 suggesting that deferiprone may cause a more 
rapid improvement in cardiac function than deferasirox. 
In a second study of 27 patients with thalassemia and 
cardiac T2* ,20 ms with LVEF of 56% or higher, cardiac 
iron measurements improved by 16% (P = 0.06) following 
18 months of treatment with deferasirox (mean ending dose 
of 33.3 mg/kg/day).110 However, cardiac T2* worsened in 
about 50% of these patients and this failure to respond was 
predicted by higher baseline liver iron concentration and 
ferritin levels.110 Similar to the previous study, no change in 
LVEF was seen over the 18 months of treatment. A third study 
of 19 patients with beta thalassemia and iron overload also 
demonstrated improvement in cardiac T2* over 18 months of 
treatment (17.2 to 21.5 ms).111 Administration of deferasirox 
(mean dose 27.6 mg/kg/day) also can prevent cardiac iron 
accumulation; in 78 patients with thalassemia without 
evidence of cardiac iron loading (cardiac T2* 20 ms), 
cardiac T2* did not worsen over a year of treatment (32 to 
32.5 ms).108 Moreover, in that study, no subjects with normal 
cardiac T2* at baseline developed an abnormal study 
(T2* ,20 ms) over the follow-up period.
The ability of deferasirox to reverse cardiac disease has 
not yet been investigated, as the prior studies all required 
normal left ventricular function for inclusion. A case report 
of a 15-year-old boy with beta thalassemia and conges-
tive heart failure showed improvement in LVEF from 33% 
to 58% with 15 months of treatment with deferasirox at 
30 mg/kg/day112 and a second report showed normalization 
of LVEF following 3 years of treatment with deferasirox 
in a 22-year-old woman with severe aplastic anemia and Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
144
Kwiatkowski
iron-related cardiac dysfunction (initial LVEF of 26.5%).113 
Before a recommendation can be made regarding the use of 
deferasirox to treat patients with iron-related cardiac disease, 
prospective studies are needed that assess the rapidity and 
degree of cardiac iron removal, improvement in left ventricular 
function, and ability to reverse iron-related cardiac complica-
tions with deferasirox compared with other chelators.
Adverse effects
The toxicity profile of deferasirox generally is similar across 
disease states.2,19,20 Gastrointestinal disturbances, including 
nausea, vomiting, and abdominal pain are common.19 Although 
usually transient and dose related, these symptoms have led to 
discontinuation of the drug in some patients. The gastrointestinal 
side effects may be related to lactose intolerance in some 
patients because lactose is present in the drug preparation.20 
Diffuse, maculopapular skin rashes that usually resolve even 
if the drug is continued, have been reported in approximately 
10% of subjects receiving deferasirox.19,20,33 Nephrotoxicity 
also can be seen with use of the drug. Approximately 33% of 
patients experience mild elevations in serum creatinine levels, 
although few patients have experienced elevations beyond the 
normal range.19,20 Rare reports of renal impairment and renal 
failure with deferasirox use have led to a black box warning 
about this side effect. Intermittent proteinuria has also been 
seen with the administration of the drug.19 Fanconi syndrome, 
a proximal renal tubular dysfunction leading to electrolyte 
abnormalities, has been reported in a several patients taking 
deferasirox, sometimes in the setting of acute illness; this 
toxicity resolved after discontinuation of the drug and 
recurred in some patients with reinstitution of the drug.114–116 
Elevations in hepatic transaminases to more than five times 
baseline values also have been reported.19,20 Fulminant hepatic 
failure has also been reported in rare cases, often in patients 
with comorbidities. Gastrointestinal bleeding also has been 
reported rarely with deferasirox use. Although more common 
in older patients with significant comorbidities, this toxicity 
has been reported in children as well.117 Cataracts or lenticular 
opacities and audiotoxicity were reported at low rates, similar 
to deferoxamine.19,20 Importantly, agranulocytosis has not 
been seen with deferasirox administration and the rare reports 
of neutropenia with deferasirox were thought unlikely to be 
drug related but rather related to the underlying hematological 
disorder.
Adherence
Adherence with deferasirox therapy has been reported to be 
better than with deferoxamine.118 Similarly, patients reported 
greater satisfaction and convenience with deferasirox in 
comparison with deferoxamine.119 In a preliminary report of 
patients participating in the Thalassemia Clinical Research 
Network comprised of subjects living in North America 
and London, UK, deferasirox was the most commonly used 
chelator at the time of enrollment (2007–2009), being taken 
by 57% of patients on chelation.118
Combination chelation therapy
Deferiprone and deferoxamine
The most extensively studied combination chelation therapy 
is that of deferiprone and deferoxamine. A variety of 
dosing regimens have been utilized82,120,121 and iron balance 
studies have shown an additive effect when the two drugs 
are administered together. A significant reduction in serum 
ferritin levels was shown with combination therapy.120,121 Most 
important, the combination of deferoxamine and deferiprone 
appears to be particularly efficacious for cardiac iron removal 
and treatment of iron-related cardiac disease. A shuttling 
hypothesis, whereby deferiprone, a smaller molecule, enters 
cardiac cells, binds iron, and then transfers it to deferoxamine 
for excretion has been proposed.122,123 Significant reduction 
in cardiac iron stores measured by MRI,121 and significant 
improvement in left ventricular shortening fraction120,121 have 
been reported using combination therapy, without unexpected 
toxicities.
The largest randomized placebo-controlled clinical trial 
compared the use of deferoxamine alone or in combination 
with deferiprone in the treatment of 65 patients with mild to 
moderate cardiac iron loading (cardiac T2* 8–20 ms).124 The 
beneficial effect of combined therapy on cardiac iron removal 
and improvement in cardiac function was confirmed. After 
a 12-month treatment period, those receiving combination 
therapy had significantly greater improvement in cardiac T2* 
(from 11.7 to 17.7 ms compared with 12.4 to 15.7 ms) and 
in LVEF (2.6% compared with 0.6%) than those receiving 
deferoxamine alone. Furthermore, in a single arm trial of 
15 patients with severe myocardial siderosis (T2* ,8 ms) 
and myocardial dysfunction, treatment with deferoxamine 
(mean dose 38 ± 10.2 mg/kg for 5.3 days/week) combined 
with deferiprone (73.9 ± 4 mg/kg/day) resulted in significant 
improvement in cardiac T2* (5.7 to 7.9 ms) and LVEF (51.2% 
to 65.6%) as well as a reduction in serum ferritin and liver 
iron concentration.125 A second, smaller, prospective study 
of combination therapy with deferoxamine and deferiprone 
compared with deferoxamine monotherapy for patients with 
established cardiac disease showed a significantly lower 
rate of cardiac events in heavily iron-loaded patients treated Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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with combined therapy (no events among nine subjects) 
compared with monotherapy (four cardiac events with three 
deaths among five subjects).126 Similarly, prospective and 
retrospective analyses have supported that the combination 
of deferoxamine and deferiprone is superior to other chelators 
in reducing cardiac iron in clinical practice.97,127
Deferasirox and deferoxamine
Limited data, consisting mostly of animal studies, small 
case series, and pilot studies, exist regarding treatment 
with deferasirox combined with deferoxamine. In an iron-
overloaded gerbil model, the addition of deferoxamine to 
deferasirox did not cause any detectable increase in organ 
toxicity above treatment with deferasirox alone.128 However, 
in that study, combination treatment with deferasirox 
and deferoxamine did not show additive iron excretion, 
suggesting that the chelators may simply compete for a 
common iron pool.128 It is unclear if this will hold true in 
humans but sequential (administered on different days) 
rather than combination (administered on the same day) 
therapy would be expected to be a better strategy if the two 
chelators simply compete for a common iron pool. Such an 
approach could limit toxicity associated with each chelator 
and improve adherence.
Limited information is available regarding the use of 
sequential or combined therapy with deferoxamine and 
deferasirox in humans. In a retrospective study, seven 
patients with thalassemia and iron overload were treated 
with deferasirox (20–30 mg/kg/day) for 4 consecutive days 
followed by deferoxamine (20–40 mg/kg/day, subcutaneously 
over 8–12 hours) for 3 days with median treatment duration 
of 25 months (range 8–32 months).129 A significant reduction 
in serum ferritin levels was evidenced and no patients 
experienced significant toxicity. In addition, overall costs 
were reduced because deferasirox was significantly more 
expensive than deferoxamine, even including the supplies 
needed for administration.
In a second preliminary report, 14 subjects with 
transfusion-dependent thalassemia with severe iron overload 
and/or evidence of organ dysfunction were treated prospec-
tively with deferoxamine (35–50 mg/kg/day for 3–7 days/
week) and deferasirox (20–30 mg/kg daily, 7 days/week).130 
In contrast to the previous report, the two drugs were given 
on the same days, rather than sequentially. After 26 weeks of 
combined therapy, a significant reduction in liver iron con-
centration from 12 to 10.6 mg/g dw was seen, but there was 
no significant change in myocardial T2*, ejection fraction, or 
serum ferritin. It remains to be seen whether these parameters 
will improve with longer follow-up. One subject died from 
sepsis and one interrupted drug treatment secondary to 
abdominal pain, but no elevations in serum creatinine or ALT 
were seen. Additional safety and efficacy data are needed 
before clinical recommendations for the combination of 
deferasirox/deferoxamine can be made.
Deferasirox and deferiprone
Combination therapy with deferasirox and deferiprone 
would be particularly desirable, as it would avoid the use 
of parenteral therapy; however, data regarding such therapy 
are lacking. In one report, two subjects who experienced 
significant toxicity during monotherapy with each chelator 
(deferoxamine, deferiprone, and deferasirox) individually 
were treated with deferasirox (30 mg/kg/day) alternating 
with deferiprone (75–85 mg/kg/day).131 The toxicities 
experienced with monotherapy were not evidenced 
and iron burden improved or remained well controlled. 
In a second report, three subjects with severe cardiac 
iron loading (T2* ,6 ms) were treated with deferasirox 
(20–40 mg/kg/day) and deferiprone (75–100 mg/kg/day) for 
7 days/week.132 After a treatment duration of 7–28 months, 
a significant improvement in cardiac T2* was evidenced, 
but with worsening of liver iron concentration in one, 
and minimal to no improvement in the other two subjects. 
Adverse events included gastrointestinal upset and 
fluctuating transaminase levels, but renal dysfunction and 
neutropenia were not seen. Prospective studies are needed to 
determine the optimal dosing regimen, efficacy, and safety 
of this treatment approach.
Other oral chelators in development
FBS0701 is a new oral chelator that has undergone Phase I 
testing in patients with transfusion-dependent anemias.133 The 
drug is a desferrithiocin derivative that has been modified 
to minimize nephrotoxicity. It binds iron in a ratio of two 
molecules of drug to one molecule of iron (tridentate). In a 
Phase Ib dose escalation study, FBS0701 was administered 
for a total of 7 days to patients with transfusion-dependent 
anemias; four different dose levels were tested (3, 8, 16, 
and 32 mg/kg).133 The mean half-life was 16.2–21.3 hours, 
supportive of daily dosing. Adverse effects were rare and 
included urinary discoloration, headache, and gastrointestinal 
symptoms. One patient with sickle cell disease experienced 
a mild prolongation of the QTc on electrocardiogram, which 
was not clearly drug-related. One serious adverse event, 
hospitalization for vaso-occlusive pain, occurred in a patient 
with sickle cell disease, also thought to be unrelated to the Journal of Blood Medicine 2011:2 submit your manuscript | www.dovepress.com
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drug. Further studies are needed to determine the effect of 
FBS0701 on iron removal and a Phase II trial is ongoing.
Conclusion
Three iron chelators, deferoxamine, deferiprone, and 
deferasirox, have undergone extensive study and are in 
clinical use worldwide, although deferiprone is not currently 
approved for use in North America. Individual properties 
of the chelators, including efficacy at both cardiac and liver 
iron removal, adverse-effect profile, tolerability, and patient 
preference should be considered in tailoring an individual’s 
chelation regimen. Trends in liver and cardiac iron burden 
and ongoing transfusional iron intake should be utilized to 
adjust the dosing of the chelator. Combination therapy with 
deferiprone and deferoxamine has been shown to be the most 
efficacious with regard to improvement in cardiac function 
and cardiac iron removal. Other chelator combinations 
require further study before routine clinical use can be 
recommended.
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